Formulating Medicinal Synthetic Aluminum Magnesium Silicate

Antimicrobial resistance (AMR) is a big concern, globally, necessitating incorporation of adjuvants for enhanced efficacies and reduction of dosages used on food animals.Cotrimoxazole , a widely used antimicrobial, is 16.70% Trimethoprim and 83.30% Sulphamethoxazole (100%), which leaves no space for adjuvants.Molecules of Aluminum magnesium silicate (AMS), approved pharmaceutical stabilizing agent, consist of nanoparticles.Stabilizing medicines prolongs time they remain at high bioavailability and nanoparticles enhance medicines` delivery to effect-targets while silicates, enhance immunity.Prolonging high-bioavailability time while enhancing medicines` delivery and patients` immunity improve efficacies so that lower dosages achieve desired effects.Using lower dosages for desired effects minimizes side effects, thereby, further enhancing immunity.Enhancing medicines` efficacies and patients` immunity terminates infections to prevent/cure AMR.Making lower dosages effective also reduces costs of medicines.Countries that lack AMS may have Aluminum silicate (AS) and Magnesium silicate (MS), approved medicines.So, AS and MS were formulated to get an AMS-brand, named Medicinal synthetic AMS (MSAMS ).To improve efficacy of Cotrimoxazole , MSAMS was formulated to it such that one dose of each of six formulations delivers recommended dosage for: Trimethoprim , Sulphamethoxazole and MSAMS .We report how to formulate MSAMS to antimicrobials to overcome AMR and develop brands.